Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.55
    -0.12 (-1.24%)

    Market Cap: $379.70M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market cap of $379.70M and an enterprise value of $304.50M. Its share count is up 36.54% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 19.80% below the market cap, as cash exceeds debt.

    Market Cap$379.70M
    Enterprise Value$304.50M
    Latest price (Nov 17, 2026)$9.55

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.46% in the quarter ended Sep 30, 2026 and grew 22.15% a year over 2 years.

    Shares Outstanding38.39M
    Shares Change (YoY)+36.54%
    Shares Change (QoQ)+2.46%
    Share Count Growth (2Y CAGR)+22.15%

    Price Statistics

    The stock is down 10.41% over 52 weeks and trades 13.26% below its 50-day average.

    Beta (1Y)1.64
    52-Week Change-10.41%
    1-Month Change+28.36%
    3-Month Change-40.39%
    6-Month Change-25.16%
    Total Return (1Y)-10.41%
    Return vs SPY (1Y)-28.59%
    Max Drawdown (1Y)-59.70%
    Max Drawdown (3Y)-84.37%
    Sharpe Ratio (1Y)-0.22
    Correlation with SPY (1Y)0.27
    50-Day Average$11.01
    200-Day Average$13.35
    52-Week Range$6.72 to $17.79
    RSI (14 Days)45.8
    Average Volume (20 Days)466.96K

    Price chart

    Financial Position

    Current assets cover 31.11x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio31.11x
    Quick Ratio31.11x
    Debt / Equity0.00x
    Interest Coverage90.25x

    Returns and Efficiency

    Return on equity is -25.86% and return on assets is -24.69% over the last 12 months.

    Return on Equity (ROE)-25.86%
    Return on Assets (ROA)-24.69%
    ROA (5Y Average)-22.63%

    Scores

    CTNM has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$85.00K
    Operating Income-$72.41M
    Pretax Income-$63.46M
    Net Income-$63.46M
    Reported EPS (TTM)-$1.77

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 95.50% of the $256.99M in total assets.

    Cash and Equivalents$75.20M
    Total Debt$0
    Net Cash$75.20M
    Net Cash Per Share$1.96
    Working Capital$241.72M
    Shareholder Equity$245.42M
    Book Value Per Share$6.39
    Total Assets$256.99M
    Total Liabilities$11.57M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$51.87M
    FCF Per Share-$1.58
    Depreciation and Amortization$2.40M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    CTNM does not pay a dividend.

    Buyback Yield-30.74%
    Shareholder Yield-30.74%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CTNM

    What is CTNM's market cap?

    Contineum Therapeutics, Inc. Class A Common Stock has a market cap of $379.70M. Its enterprise value, which adds debt and subtracts cash, is $304.50M.

    How many shares of CTNM are outstanding?

    Contineum Therapeutics, Inc. Class A Common Stock has 38.39M shares outstanding. The count is up 36.54% from a year earlier.

    Does CTNM pay a dividend?

    No. Contineum Therapeutics, Inc. Class A Common Stock does not pay a dividend.

    How much debt does CTNM have?

    Contineum Therapeutics, Inc. Class A Common Stock has $0 of total debt and $75.20M of cash and equivalents, a net cash position of $75.20M.